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Abstract Exposure of rat glomerular mesangial cells to transforming growth factor jIz (TGFBJ stimulates a biphasic mitogen-activated protein 
kinase (MAP kinase) activation. A rapid increase in activity (maximal at 10 min) is followed by a second persistent level of activity which steadily 
increases over 24 h. The second peak of MAP kinase activity is markedly attenuated by the protein synthesis inhibitor cycloheximide and consequently 
is paralleled by a pronounced de-novo synthesis of p42 and p44 MAP kinases as measured by immunoprecipitation of [3sS]methionine-labeled 
mesa&al cells. In addition, an increased de-novo synthesis of MAP kinase kinase (MEK), the upstream activator of MAP kinase, is observed in 
response to TGFpz stimulation. We propose that TGFB-induced activation and de-novo synthesis of MAP kinases and MEK is important for the 
multifunctional actions of this cytokine in mesangial cells and its role in disease states characterized by excessive fibrosis. 
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1. Introduction 
The transforming growth factor /I (TGFB) family of mole- 
cules are small homo- and heterodimeric polypeptides origi- 
nally purified from platelets [l], placenta [2] and kidney [3]. 
These multifunctional molecules are produced by neoplastic 
and normal cells, including macrophages and lymphocytes (for 
review see [4,5]). In the kidney, besides the presence of TGF/?, 
the existence of high-affinity TGFB receptors on glomerular 
endothelial, epithelial and mesangial cells has been reported [6]. 
TGF/I increases the production of extracellular matrix compo- 
nents, especially of collagen and fibronectin by mesangial cells 
[6] and blunts mechanisms responsible for extracellular matrix 
degradation [7]. In addition, TGFB suppresses interleukin l- 
and tumor necrosis factor d-triggered expression of secretory 
phospholipase A2 [8,9] and inducible nitric oxide synthase [lo] 
in mesangial cells. Furthermore, TGF/I was shown to modulate 
mesangial cell proliferation in response to growth factor stimu- 
lation [6,11,12]. In murine mesangial cells, TGFB acts as a 
growth promotor at higher cell densities and inhibits cell prolif- 
eration at lower cell densities [6]. However, in-vivo the prolifer- 
ative effects of TGF/I dominates as shown recently by an in vivo 
transfection technique that allows to selectively overexpress 
TGFB in the kidney [13]. 
Very little is known about the mechanisms of signal 
transduction by the different receptors for the TGFB family. 
Mitogen-activated protein kinases (MAP kinases) are impor- 
tant intermediates in signal transduction pathways that are 
stimulated by many agents, including most if not all mitogens 
[ 14-161. Activation of MAP kinases results from phosphoryla- 
tion of adjacent tyrosine and threonine residues within MAP 
kinase by a dual specificity kinase termed MAP kinase kinase 
(MEK). We therefore set out to investigate whether TGF/I 
activates this important class of signaling enzymes thought to 
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mediate mitogenic events within many cell types [14-161. We 
report here for the first time that TGFB induces a biphasic 
activation of MAP kinase activity. Most importantly, our data 
demonstrate the TGFB causes a delayed de-novo synthesis of 
MAP kinases and MEK which may guarantee prolonged activ- 
ity of this signaling cascade for cell proliferation. 
2. Materials and methods 
2.1. Chemicals 
Protein A-Sepharose 4B-CL was purchased from Pharmacia Fine 
Chemicals, Uppsala, Sweden; [3SS]methionine (specific activity 55.5 Bq/ 
mM) was from Amersham International, Zilrich, Switzerland; recombi- 
nant human TGF/I, was kindly provided by Drs. Nice Cerletti, David 
Cox and Garry McMaster, Ciba-Geigy Ltd., Switzerland; all cell cul- 
ture nutrients were from Gibco-BRL, Basel, Switzerland; all other 
chemicals were from either Merck, Darmstadt, Germany, or Fluka, 
Buchs, Switzerland. 
2.2. Cell culture 
Rat renal mesangial cells were cultivated as described previously [IO]. 
In a second step, single cells were cloned by limited dilution on 96- 
microwell plates. Clones with apparent mesangial cell morphology were 
used for further processing. The cells were grown in RPM1 1640 supple- 
mented with 10% (v/v) fetal-calf serum, penicillin (100 units/ml), strep- 
tomycin (lOO@ml) and bovine insulin (0.66 units/ml). Mesangial cells 
exhibited the typical stellate morphology. Moreover, there was positive 
staining for the intermediate filaments desmin and vimentin, which is 
considered to be specific for myogenic cells, positive staining for Thy 
1.1 antigen, and negative staining for factor-VIII-related antigen and 
cytokeratin, which excludes endothelial and epithelial contaminations. 
Generation of InsP, upon activation of angiotensin II AT,-type recep 
tor (17) was used as a functional criterion for characterizing the cloned 
cell line. For the reported experiments, passages 8-19 of mesangial cells 
were used. 
2.3. Peptide synthesis and generation of antibodies 
For p44maPk and p42mPk synthetic peptides based on the C-terminal 
sequences (IFQETARFQPGAPEAP for p44mapk and IFEETARFQP- 
GYRS for p42”pk) were synthesized, coupled to keyhole-limpet 
haemocyanin, and used to immunize rabbits. The anti-p44”@ antise- 
rum and the anti-p42”Pk antiserum recognized specially the p44- 
isoform and the p42-isoform, respectively. A second antiserum which 
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specifically recognized the p42-isoform was kindly provided by Dr. 
M.J. Dunn. Cleveland 1181. For MEK a synthetic peptide based on the 
N-terminal’ sequence oi murine MEK- 1 was synthesized and coupled 
to keyhole-limpet haemocyanine and used to immunize rabbits. The 
sequence of the peptide was CPKKKPTPIQLNPFAPDG. 
TGF&( ng /ml) 
co 0.1 1 10 50 
2.4. Cell labeling and immunoprecipitation 
Confluent mesangial cells in 100 mm-diameter dishes were washed 
with PBS and incubated in methionine-free DMEM in the absence or 
presence of the stimulators for the indicated time periods. For the last 
4 h of incubation 1”Slmethionine was added (100 &i/plate). After 
labeling, cells were’washed twice with ice-cold‘PBS: CeBs were then 
scraped directly into 1 ml of ice-cold lysis buffer (50 mM Tris-HCl, pH 
7.9150 mM-NaCl/lO% glycerol/l% Triton X-100/2 mM EDTA/2 mM 
EGTA/40 mM /7-glycerophosphatel50 mM sodium fluoride/l0 mM 
sodium pyrophosphaW200 PM sodium orthovanadate/lO .ug of 
leupeptin/mY200 U of aprotinin/mYl PM pepstatin A/l mM phen- 
ylmethanesulphonyl fluoride) and homogenized with 10 passes through 
a 26-gauge needle fitted to a l-ml syringe. The homogenate was centri- 
fuged for 10 min at 14,000 x g and the supernatant aken for im- 
munoprecipitation. Samples of 1 ml volume, containing 100 x lo6 cpm 
of labelled proteins, 5% fetal calf serum and 1.5 mM iodoacetamide in 
lysis buffer, were incubated for 4 h at 4°C. Then 100 ~1 of a 50% slurry 
of protein A-Sepharose 4B-CL in PBS was added and the mixture was 
incubated for 1.5 h at room temperature under mild shaking. After 
centrifugation for 5 min at 3,000 x g immunocomplexes were washed 
3 times with 1 ml of a low salt buffer (50 mM Tris-HCl, pH 7.5/150 mM 
NaCl/0.2% Triton X-100/2 mM EDTA/2 mM EGTA/O.l% SDS), 
3 times with 1 ml of a high salt buffer (50 mM Tris-HCl, pH 7.5/500 
mM NaCl/0.2% Triton X-100/2 mM EDTA/2 mM EGTA/O.l% SDS) 
and once with 1 ml of 10 mM Tris. Pellets were boiled for 5 min in 50 
~1 Laemmli dissociation buffer and subjected to SDS-PAGE (10% 
acrylamide gel). After fixing in 25% isopropanol, 10% acetic acid, the 
gels were soaked for 30 min in 16% sodium salicylate solution and then 
dried and exposed to Hyperhlm MP at - 70°C using two intensifying 
screens. 
2.5. h4BP kinase assay 
Quiescent mesangial cells in 60 mm-diameter dishes were stimulated 
with the indicated concentrations of agonists. To stop the reaction, the 
cells were washed with PBS and homogenized in 1 ml of icecold lysis 
buffer. For immunoprecipitation 50 pg of cell extracts were incubated 
overnight at 4°C with an antiserum reactive with ~42”“~~ in a dilution 
of 1: 200. All further steps were performed following the immunopre- 
cipitation protocol1 described above. Finally the beads were incubated 
for 15 min at 30°C in 50 ~1 of kinase buffer including 20 pg myelin basic 
protein, 20 PM ATP and 4 PCi [r-‘*P]ATP. The reaction was termi- 
nated by adding 40 ~1 Laemmli dissociation buffer and subjected to 
SDS-PAGE (13% acrylamide gel). After tixing in 25% isopropanol, 
10% acetic acid, the gels were exposed to Hyperhlm MP for 3-5 h or 
evaluated by Phosphor imaging. 
3. Results 
TGFfi, is a potent stimulator of MAP kinase activity in 
mesangial cells and induces a concentration-dependent activa- 
tion of the enzyme as shown in Fig. 1. Maximal stimulation is 
observed at 10 ng/ml TGFj12 and half-maximal activity is ob- 
tained at 0.42 ng/ml TGF/&. Treatment of quiescent mesangial 
cells with 25 ng/ml TGFB, triggers a biphasic activation of the 
enzyme as shown in Fig. 2. An early peak of activation is 
observed at 10 min after exposure of cells to TGFjIz and is 
followed by a second increase in MAP kinase activity which 
steadily increases over 24 h (Fig. 2A and B). The degree of 
activation of MAP kinase is paralleled by an increased phos- 
phorylation of p42 and p44 MAP kinases as determined by 
immunoprecipitation of p42 and p44 MAP kinases from [3zPi]- 
labelled mesangial cells (data not shown). Inhibition of protein 
synthesis by cycloheximide (10 PM) has no effect on the rapid 
first phase of MAP kinase activation but it markedly attenuates 
Fig. 1. Concentration dependence of TGFB,-stimulated p42 MAP ki- 
nase activity in mesangial cells. Mesangial cells were treated for 10 min 
with the indicated concentrations of TGFp2. Cells were then lysed and 
cell extracts were immunoprecipitated with a specific anti-p42 MAP 
kinase antiserum at a dilution of 1:200. Myelin basic protein kinase 
activity in immunocomplexes was analyzed by SDS-PAGE (13% 
acrylamide gel) and autoradiography. Bands were quantified by Phos- 
phor Imaging. 
the second peak of kinase activity as shown in Fig. 2B, thus 
suggesting that protein synthesis is required for sustained MAP 
kinase activity. To study whether TGFB, has an effect on de- 
novo synthesis of MAP kinase, mesangial cells were stimulated 
with TGFj& (25 @ml) for different time periods and 
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Fig. 2. Kinetics of p42 MAP kinase activation by TGF/3,. Mesangial 
cells were treated with TGFBZ (25 ng/ml) either in the presence (A) or 
absence (0) of cycloheximide (10 PM) for the indicated time periods. 
Cells were then lysed and cell extracts were immunoprecipitated with 
a specific anti-p42 MAP kinase antiserum at a dilution of 1: 200. Myelin 
basic protein kinase activity in immunocomplexes was analysed by 
SDS-PAGE (13% acrylamide gel) and autoradiography. A typical ex- 
periment (without cycloheximide) is shown in (A). Bands were quanti- 
fied by Phosphor Imaging and the data in (B) are means of three 
independent experiments. Significant differences from corresponding 
stimulation with TGF/? in the absence of cycloheximide: **P c 0.01; 
ANOVA. 
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[35S]methionine was added for the last 4 h of the stimulation 
period. p42 MAP kinase was immunoprecipitated with a spe- 
cific polyclonal antibody and subject to SDS-PAGE. As shown 
in Fig. 3 only a faint band of p42 MAP kinase labelling is 
detected in unstimulated cells. Addition of TGFpz dramatically 
upregulates biosynthesis of the enzyme, an effect that is maxi- 
mal at 6 h after exposure of the cells to the cytokine and remains 
at high levels for at least 24 h (Fig. 3). Comparable data were 
obtained for p44 MAP kinase (data not shown). A pronounced 
effect of TGFB, is also detected for MEK (Fig. 4). Already 
under control conditions a strong incorporation of label into 
MEK is observed, suggesting a higher turn-over rate of MEK 
as compared to p42 MAP kinase. Addition of TGFBz results 
in a potent increase in MEK biosynthesis after 4-6 h (Fig. 4). 
4. Discussion 
TGF/? is a multifunctional cytokine regulating quite diverse 
cellular activities including differentiation, extracellular matrix 
production and cell proliferation. Three mammalian isoforms 
TGFB,, TGF/?, and TGF/?, initiate these responses by binding 
with high affinity to several distinct receptors [4,.5]. A hetero- 
merit receptor complex composed of both type I and type II 
receptors is essential for TGFB signal transduction. Both the 
type I as well as the type II receptor for TGF/3 have intracellular 
serine/threonine protein kinase domains. However, aport from 
these kinase domains of the TGF/_I receptors very little is known 
about the signalling events that mediate gene expression in cells 
exposed to TGFB. TGF/3 does not activate phosphoinositide 
turnover, Ca” mobilization, protein kinase C activation or 
Na+/H’ antiport stimulation [5]. In mink lung epithelial cells the 
antiproliferative action of TGF/I is overcome by microinjection 
of oncogenic Ha-ras [19]. In contrast, under different condi- 
tions, TGF/I results in a rapid activation of ras proteins in rat 
intestinal epithelial cells [20] and a colon carcinoma cell line 
[21]. Ras is a common signalling element that is known to 
activate the MAP signalling cascade and thereby triggers cell 
TGF(32 
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Fig. 3. Kinetics of p42 MAP kinase de-novo synthesis by TGFB,. 
Confluent mesangial cells were stimulated with vehicle (co) or TGFB, 
(25 ng/ml) for the indicated time periods and incorporatation of 
[‘%]methionine was measured by immunoprecipitation f p42 MAP 
kinase (p42m”pk) and subsequent SDS-PAGE analysis as described in 
section 2. Similar results were obtained in three independent experi- 
ments. 
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Fig. 4. Kinetics of MEK de-novo synthesis by TGF/& Confluent me- 
sangial cells were stimulated with vehicle (co) or TGFB, (25 @ml) for 
the indicated time periods and incorporation of [“Slmethionine was 
measured by imxnunoprecipitation of MEK and subsequent SDS- 
PAGE analysis as described in section 2. Similar results were obtained 
in three independent experiments. 
proliferation in many cell types [14-161. We therefore hypothe- 
sized that TGFB might activate MAP kinase activity in me- 
sangial cells. Our data are the first report of p42 MAP kinase 
activation in the signal transduction pathway of TGFB,. More- 
over, we demonstrate for the first time an increased de-novo 
synthesis of p42 MAP kinase and MEK in response to TGFB, 
stimulation. A coordinate, biphasic stimulation of p44 MAP 
kinase has also been observed in hamster fibroblasts exposed 
to thrombin and is paralleled by a biphasic increase in ribo- 
somal S6 kinase activity [22]. The authors, however, did not 
check whether the second peak of MAP kinase activity is due 
to increased de-novo synthesis of the enzymes as shown here 
for mesangial cells. Recently Wang et al. [23] reported that 
endothelin 1 biphasically stimulates p42 MAP kinase activity 
in mesangial cells. In contrast to our data with TGFB,, cyclo- 
heximide does not inhibit endothelin 1 activation of p42 MAP 
kinase neither at early nor at late points [23]. Moreover, we 
have reported that interleukin 1 stimulates MAP kinase activa- 
tion and de-novo synthesis of p42 MAP kinase in a manner 
comparable to TGFB, [24]. Taken together, these data suggest 
that whereas cytokines such as TGF/3, or interleukin 1 are able 
to trigger translational induction of MAP kinase, G-protein 
coupled receptor agonists such as endothelin 1 cause long-term 
activation of MAP kinase by phosphorylation rather than by 
gene expression and protein synthesis. The increased de-novo 
synthesis of MAP kinases and MEK reported in this and an- 
other report [24] may be of crucial importance for cytokine- 
induced activation of MAP kinase cascade responsible for initi- 
ating G, to S-phase transition or other long-term actions of 
cytokines in renal mesangial cells. Additional studies are re- 
quired to unravel the mechanism of increased biosynthesis of 
MAP kinases and MEK in mesangial cells and to evaluate its 
pathophysiological relevance. 
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